...Thank you, Didi. Thank you, everyone, for joining us today. It's been 6 years since Steve and I became CEO and CFO and we've turned this company from losing well over $100 million a year to our first profitable quarter in our history. We've helped over 20,000 people on a MannKind manufactured product last quarter and our pipeline is moving faster than ever to help more as we continue to live our mission to help patients live a better life. As we think about our highlights this quarter, we've made great progress on the clinical and financial aspects of our company. In the orphan lung space, we've seen Tyvaso royalty revenue of over $20 million and manufacturing of $13 million. On the pipeline, MNKD-101 cannot be in a better position. We came from our last earnings call when we just had learned of a fire in our facility at our partnership in Germany to successfully moving CMC here in Danbury and we have manufactured our first clinical batch in record time. Our MNKD-201, our inhaled nintedanib...
